Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-CAS bosentan trial in coronary artery spasm
NL-OMON59980Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Coronary vasospasm (CAS) and coronary functional abnormalities (CFA) comparing Bosentan adjunctive therapy with Placebo adjunctive therapy (2 arms). Started Sep 2024; status: recruiting.
02
Drugs
bosentan
03
Conditions
Coronary vasospasm (CAS)coronary functional abnormalities (CFA)
Beyond the preview
Go deeper on NL-OMON59980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59980.